Business Context and Reporting Period
This Form 8-K was filed by Leisure Acquisition Corp. (LACQ) on June 7, 2021. The filing reports on a material definitive agreement entered into in connection with a proposed business combination with Ensysce Biosciences, Inc. LACQ is a special purpose acquisition company (SPAC) listed on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for the reporting period. The document focuses exclusively on a corporate transaction regarding warrant restructuring rather than operational financial performance.
Material Changes
- Warrant Exchange: On June 7, 2021, LACQ entered into exchange agreements with holders of Private Placement Warrants and other private warrants.
- Volume: An aggregate of 8,391,289 warrants were exchanged for new private warrants.
- Terms: The new private warrants retain the same terms as the original Private Placement Warrants but are not issued under the original Warrant Agreement and are non-transferable except to permitted transferees.
- Accounting Impact: The exchange is intended to enable LACQ to classify the private warrants as equity rather than liabilities in its financial statements following the proposed transaction with Ensysce.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management believes the warrant exchange is a necessary step to facilitate the proposed merger with Ensysce. The company intends to file a registration statement on Form S-4, which will include a proxy statement/prospectus for stockholder approval of the transaction.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Key risks identified include:
- Failure to successfully or timely consummate the business combination.
- Delays or denial of regulatory approvals.
- Failure to obtain stockholder approval.
- Inability to maintain Nasdaq listing.
- Significant redemption requests by LACQ stockholders.
Investor Verification Checklist
- Verify the final terms of the proposed business combination with Ensysce Biosciences, Inc. in the upcoming Form S-4 filing.
- Confirm the impact of the warrant exchange on LACQ's balance sheet classification (equity vs. liability) in subsequent financial reports.
- Monitor the status of the proxy statement/prospectus and the scheduled special meeting for stockholder voting.
- Review the "Risk Factors" section in LACQ's Form 10-K for the year ended December 31, 2020, for detailed risk disclosures.